THE government's decision to eliminate pre-approval for advertising of therapeutic goods will mean the Therapeutic Goods Administration requires "strong and timely compliance powers," according to John Skerritt, head of the Health Products Regulation Group which oversees the TGA.
Skerritt told yesterday's ASMI conference in Sydney the changes will see a new mechanism for managing complaints, while the TGA's investigation and enforcement programs will also be broadened as a result.
He said the TGA was currently developing options papers on areas such as S3 advertising and the new complaints process, with stakeholder workshops to be held in the coming months.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Oct 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Oct 16
